Aman U Buzdar Selected Research

Breast Neoplasms (Breast Cancer)

09/2008	Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.
03/2008	Clinical experience with epothilones in patients with breast cancer.
02/2008	Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer.
01/2008	Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.
12/2007	Preoperative chemotherapy treatment of breast cancer--a review.
11/2007	Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.
10/2007	Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
05/2007	Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer.
05/2007	Adjuvant chemotherapy for high-risk operable breast cancer.
02/2007	Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
01/2007	CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
01/2007	Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
11/2006	Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.
09/2006	Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
09/2006	Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer.
09/2006	Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.
07/2006	Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer.
06/2006	Anastrozole for breast cancer: recent advances and ongoing challenges.
06/2006	Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer.
05/2006	Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
04/2006	Letrozole or tamoxifen in early breast cancer.
02/2006	Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
12/2005	Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
11/2005	Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer.
11/2005	Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
10/2005	Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
09/2005	Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
06/2005	Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
06/2005	Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
01/2005	Aromatase inhibitors: changing the face of endocrine therapy for breast cancer.
12/2004	Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
11/2004	Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
09/2004	Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer.
08/2004	Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group.
06/2004	The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.
05/2004	T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
04/2004	Preoperative chemotherapy for breast cancer.
02/2004	Letrozole in breast cancer.
02/2004	Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.
01/2004	Paclitaxel in early breast cancer: a viewpoint by Aman U. Buzdar.
11/2003	Aromatase inhibitors in breast cancer therapy.
10/2003	Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy.
10/2003	Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer.
10/2003	Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation.
09/2003	'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
05/2003	Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection.
05/2003	A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
03/2003	Estrogen receptors and distinct patterns of breast cancer relapse.
11/2002	A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
10/2002	Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience.
07/2002	Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy.
05/2002	Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
04/2002	A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility.
01/2002	Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.

Articles by Research Topic

Disease

54	Breast Neoplasms (Breast Cancer) 09/2008 - 01/2002
9	Carcinoma (Carcinomatosis) 06/2006 - 04/2003
5	Neoplasms (Cancer) 11/2006 - 07/2002
3	Neoplasm Metastasis (Metastasis) 12/2005 - 10/2005
1	Obesity 09/2008
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2007
1	Lobular Carcinoma 01/2005
1	Pneumonia (Pneumonitis) 11/2004
1	Colitis 10/2004
1	Male Breast Neoplasms (Male Breast Cancer) 06/2002

Drug/Important Bio-Agent (IBA)

11	Paclitaxel (Taxol)FDA LinkGeneric 01/2007 - 05/2002
7	Tamoxifen FDA LinkGeneric 11/2007 - 01/2002
7	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2006 - 01/2002
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2007 - 01/2002
5	Fluorouracil (Carac)FDA LinkGeneric 01/2007 - 01/2002
5	anastrozole (Arimidex)FDA Link 06/2006 - 06/2002
5	Aromatase InhibitorsIBA 11/2005 - 05/2003
4	letrozole (Femara)FDA Link 05/2007 - 02/2004
4	trastuzumab (Herceptin)FDA Link 01/2007 - 06/2005
3	Epirubicin (Ellence)FDA LinkGeneric 01/2007 - 06/2005
2	Epidermal Growth Factor Receptor (EGF Receptor)IBA 01/2007 - 06/2005
2	fulvestrant (Faslodex)FDA Link 09/2006 - 09/2004
2	Estrogens (Estrogen)FDA Link 09/2004 - 02/2004
1	Epothilones (Epothilone)IBA 03/2008
1	Aromatase (CYP19)IBA 02/2008
1	LY 353381 (LY353381)IBA 11/2007
1	HormonesIBA 05/2006
1	Triethylenetetramine (Trien)IBA 02/2006
1	taxaneIBA 10/2004
1	TaxoidsIBA 07/2004
1	Protein Kinases (Protein Kinase)IBA 02/2004
1	Amantadine (Aman)FDA LinkGeneric 01/2004
1	RNA (Ribonucleic Acid)IBA 06/2003
1	Estrogen ReceptorsIBA 03/2003

Therapy/Procedure

29	Drug Therapy (Chemotherapy) 09/2008 - 04/2002
5	Adjuvant Chemotherapy 05/2007 - 05/2002
5	Mastectomy (Mammectomy) 07/2006 - 07/2002
3	Neoadjuvant Therapy 01/2008 - 06/2005
1	Aftercare (After-Treatment) 02/2004
1	Hematopoietic Stem Cell Transplantation 05/2003